MYLAN-ATORVASTATIN TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

ATORVASTATIN (ATORVASTATIN CALCIUM)

Pieejams no:

MYLAN PHARMACEUTICALS ULC

ATĶ kods:

C10AA05

SNN (starptautisko nepatentēto nosaukumu):

ATORVASTATIN

Deva:

80MG

Zāļu forma:

TABLET

Kompozīcija:

ATORVASTATIN (ATORVASTATIN CALCIUM) 80MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

90

Receptes veids:

Prescription

Ārstniecības joma:

HMG-COA REDUCTASE INHIBITORS

Produktu pārskats:

Active ingredient group (AIG) number: 0133055004; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2016-05-20

Produkta apraksts

_ _
_ _
_Page 1_
I
PRODUCT MONOGRAPH
PR
MYLAN-ATORVASTATIN
ATORVASTATIN CALCIUM TABLETS
10 MG, 20 MG, 40 MG AND 80 MG ATORVASTATIN
LIPID METABOLISM REGULATOR
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
DATE OF REVISION : MAY 3, 2016
SUBMISSION CONTROL NO.: 194039
_ _
_Page 2 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
5
WARNINGS AND PRECAUTIONS
............................................................................................
5
ADVERSE REACTIONS
............................................................................................................
11
DRUG INTERACTIONS
............................................................................................................
14
DOSAGE AND ADMINISTRATION
........................................................................................
22
OVERDOSAGE
..........................................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
24
STORAGE AND STABILITY
....................................................................................................
27
SPECIAL HANDLING INSTRUCTIONS
.................................................................................
27
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................... 27
PART II: SCIENTIFIC INFORMATION
..................................................................................
28
PHARMACEUTICAL INFORMATION
.......................................